Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis

Department of Neurology, Keio University School of Medicine, Tokyo, Japan. Electronic address: .
Journal of neuroimmunology (Impact Factor: 2.47). 04/2013; 258(1-2). DOI: 10.1016/j.jneuroim.2013.03.001
Source: PubMed


There are no immunological markers to predict the prognosis of thymoma-associated myasthenia gravis (MG). Clinical and immunological factors associated with thymoma recurrence or MG relapse were examined by logistic analyses in 56 Japanese patients with thymoma-associated MG. Patients with anti-Kv1.4 antibodies showed higher frequencies of thymoma recurrence and MG relapse compared to those without. Anti-Kv1.4 antibody, Masaoka stage 4, World Health Organization type B3, and adjuvant radiotherapy were associated with thymoma recurrence. Multivariate analyses showed that anti-Kv1.4 antibody was the only independent factor associated with MG relapse. Anti-Kv1.4 antibody is a useful predictor of the prognosis of thymoma-associated MG.

8 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Of 72 patients with thymoma who were studied, 47 (65%) had myasthenia gravis when the tumor was recognized and excised. seven of the remaining 25 patients (28%) who had no myasthenia gravis when their thymoma was excised developed myasthenia gravis 2 weeks to 6 years (mean 3 years) after total removal of the thymoma and of any adjacent thymus. The 7 patients constituted 0.9% of 750 patients with myasthenia gravis, 10% of 72 patients with thymoma, and 13% of 54 patients with myasthenia gravis and thymoma or a history of thymoma. The incidence of thymoma in 750 patients with myasthenia gravis was 6%. Among the 72 patients with thymoma there were 4 with pancytopenia, 4 with red cell hypoplasia, 4 with polymyositis, and 1 with giant cell polymyositis and myocarditis. Of 1,655 patients with thymoma reported in the literature, myasthenia gravis was present in 30%, and of 3,316 patients with myasthenia gravis, thymoma was found in 9%. Myasthenia gravis began 2 weeks to 6 years (mean 1.5 years) after total removal of thymoma and of adjacent thymus in 33 patients. Ten of these patients who died of myasthenia gravis had a significantly longer interval between thymectomy and the onset of myasthenia gravis than 5 patients who went into complete remission. Since 7 of 10 patients whose mediastinum was later re-explored had no residual thymic tissue, it is likely that in the majority of patients thymic tissue was absent when myasthenia gravis appeared. Among the 33 patients there were 3 who also had red cell hypoplasia, 4 polymyositis, 4 candidiasis and 1 gastric carcinoma. The literature survey suggests that onset of myasthenia gravis after total removal of a thymoma may occur in about 2% of patients with thymoma, 3% of patients with thymoma and without myasthenia gravis, and 7% of patients with myasthenia gravis and thymoma or a history of thymoma. The onset of myasthenia gravis months to years after removal of a thymoma and of adjacent thymus provides evidence against a direct and immediate causal relationship between thymoma or the thymus and myasthenia gravis. Since the life span of some thymus-derived lymphocytes is very long, probably several years, the peripheral pool of these lymphocytes may be the link in a causal relationship that may be indirect and initiated prior to thymectomy. However, there would have to be a change in these lymphocytes, or some other alteration unrelated to the presence of thymic tissue, to explain the development of myasthenia gravis.
    Medicine 10/1978; 57(5):411-33. DOI:10.1097/00005792-197809000-00002 · 5.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We have identified a novel autoantibody reactive with all three classes of RNA polymerases, well-characterized nuclear enzymes, in sera from patients with systemic sclerosis (SSc). After incubation with [35S]methionine-labeled HeLa cell extracts, 14 of 275 SSc sera immunoprecipitated 12 or 14 proteins with similar molecular weights as those of several subunit proteins of eukaryotic RNA polymerases I, II, and III. Purified IgG from these two types of sera inhibited RNA transcription catalyzed by RNA polymerases I, II, and III in vitro. Immunoblot analysis using RNA polymerase-enriched fraction showed that the majority of these sera reacted with 42- or 25-kD protein. Anti-RNA polymerase antibody was highly specific to SSc, especially to diffuse cutaneous SSc. Clinical features associated with this antibody included a high frequency of heart and kidney involvement and a poor survival rate at 5 yr after first visit. These findings indicate that the autoantibody to three classes of RNA polymerases is a new marker for a unique subset of diffuse cutaneous SSc.
    Journal of Clinical Investigation 05/1993; 91(4):1399-404. DOI:10.1172/JCI116343 · 13.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We compared 42 myasthenia gravis (MG) patients with thymoma with 42 generalized MG patients without thymoma using a modified Osserman classification. The mean Osserman grades at diagnosis, 6 months, and 5 and 10 years post-thymectomy did not differ between groups. Our results indicate that thymoma is not a negative determinant for the long-term clinical outcome of MG.
    Neurology 11/1998; 51(4):1198-200. DOI:10.1212/WNL.51.4.1198 · 8.29 Impact Factor
Show more